Efficacy of stereotactic radiation therapy for the treatment of confirmed or presumed canine glioma
Veterinary and Comparative Oncology · 2023
DOI: 10.1111/vco.12920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2023. Verfasst von Erin Trageser und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort…. Hauptthemen laut MEDLINE: Radiosurgery, Dog Diseases, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Intracranial gliomas are the second most common brain tumour in dogs. Radiation therapy provides a minimally invasive treatment option for this tumour type. Earlier publications reporting on the use of non‐modulated radiation therapy suggested a poor prognosis for dogs with glioma, with median survival times ranging between 4 and 6 months; more recent literature utilizing stereotactic radiation therapy (SRT) demonstrates that the prognosis for canine gliomas may be more promising, with survival times closer to 12 months. A single institution retrospective study was performed between 2010 and 2020 investigating the outcomes of dogs with biopsy‐confirmed glioma or a presumptive diagnosis of intra‐cranial glioma based on MRI characteristics that were treated with SRT. Twenty‐three client‐owned dogs were included. Brachycephalic breeds were overrepresented, totalling 13 dogs (57%). SRT protocols included 16 Gy single fraction ( n = 1, 4%), 18 Gy single fraction ( n = 1, 4%), 24 Gy in 3 daily fractions ( n = 20, 91%), or 27 Gy in four daily fractions ( n = 1, 4%). Twenty‐one dogs (91%) had improvement of their presenting clinical signs following SRT. Median overall survival time (MST) was 349 days (95% CI, 162–584). Median disease specific survival time was 413 days (95% CI, 217–717). When SRT is incorporated into the management plan for dogs with confirmed or presumed intracranial glioma, a median survival time of approximately 12 months may be achievable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA.
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA.
ORCID-Profile: Erin Trageser, Tiffany Martin, Mary-Keara Boss
Zitieren
APA
Trageser, E., Martin, T., Burdekin, B., Hart, C., Leary, D., LaRue, S., & Boss, M. K. (2023). Efficacy of stereotactic radiation therapy for the treatment of confirmed or presumed canine glioma. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12920
Vancouver
Trageser E, Martin T, Burdekin B, Hart C, Leary D, LaRue S, et al. Efficacy of stereotactic radiation therapy for the treatment of confirmed or presumed canine glioma. Veterinary and Comparative Oncology. 2023. doi:10.1111/vco.12920
BibTeX
@article{Trageser2023,
author = {Trageser, Erin and Martin, Tiffany and Burdekin, Braden and Hart, Cullen and Leary, Del and LaRue, Susan and Boss, Mary-Keara},
title = {Efficacy of stereotactic radiation therapy for the treatment of confirmed or presumed canine glioma},
journal = {Veterinary and Comparative Oncology},
year = {2023},
doi = {10.1111/vco.12920}
}
EUVIMED